Blood Journal
Leading the way in experimental and clinical research in hematology

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

  1. Bertrand Coiffier1,
  2. Catherine Thieblemont2,
  3. Eric Van Den Neste3,
  4. Gérard Lepeu4,
  5. Isabelle Plantier5,
  6. Sylvie Castaigne6,
  7. Sophie Lefort7,
  8. Gérald Marit8,
  9. Margaret Macro9,
  10. Catherine Sebban10,
  11. Karim Belhadj11,
  12. Dominique Bordessoule12,
  13. Christophe Fermé13, and
  14. Hervé Tilly14
  1. 1Hospices Civils de Lyon and Université Lyon-1, Lyon, France;
  2. 2Hôpital Saint-Louis, Paris, France;
  3. 3Université Catholique de Louvain, Brussels, Belgium;
  4. 4Centre Hospitalier Général Henri Duffaut, Avignon, France;
  5. 5Hôpital V Provo, Roubaix, France;
  6. 6Hôpital André Mignot, Versailles, France;
  7. 7Centre Hospitalier, Brive, France;
  8. 8Groupe Hospitalier du Haut Leveque, Pessac, France;
  9. 9Centre Hospitalier Universitaire Cote de Nacre, Caen, France;
  10. 10Centre Leon Bérard, Lyon, France;
  11. 11Hôpital Henri Mondor, Creteil, France;
  12. 12Centre Hospitalier Dupuytren, Limoges, France;
  13. 13Institut Gustave Roussy, Villejuif, France; and
  14. 14Centre Henri Becquerel, Rouen, France


We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 10 years. Clinical event information was updated in all living patients (with the exception of 3 patients) in 2009. Survival end points were improved in patients treated with R-CHOP: the 10-year progression-free survival was 36.5%, compared with 20% with CHOP alone, and the 10-year overall survival was 43.5% compared with 27.6%. The same risk of death due to other diseases, secondary cancers, and late relapses was observed in both study arms. Relapses occurring after 5 years represented 7% of all disease progressions. The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP. Our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.

  • Submitted March 23, 2010.
  • Accepted May 27, 2010.
View Full Text